Accordingly, studies on dissecting the roles and clinical potential of YY1 in the TME revealed that although it is mostly overexpressed in the majority of cancers [51,52], different conclusions regarding the survival, prognosis, and other clinical implications of its expression analysis can be drawn across different tumors, as the functions of YY1 seem to be diversified in a pan-cancer context [52,53]. Here, YY1 is linked to cancer.